Last reviewed · How we verify
Full dose of DOAC
Direct oral anticoagulants (DOACs) inhibit specific clotting factors to prevent blood clot formation.
Direct oral anticoagulants (DOACs) inhibit specific clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Acute coronary syndrome (in combination with antiplatelet therapy).
At a glance
| Generic name | Full dose of DOAC |
|---|---|
| Sponsor | University Hospital, Brest |
| Drug class | Direct oral anticoagulant (DOAC) |
| Target | Factor Xa or Factor IIa (thrombin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
DOACs are a class of anticoagulants that work by directly inhibiting either Factor Xa (apixaban, rivaroxaban, edoxaban) or Factor IIa/thrombin (dabigatran), key enzymes in the coagulation cascade. By blocking these factors, DOACs prevent the formation of thrombin and subsequent fibrin clot formation, reducing thrombotic events while maintaining some residual coagulation capacity.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Acute coronary syndrome (in combination with antiplatelet therapy)
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Dyspepsia
- Intracranial hemorrhage
Key clinical trials
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing (PHASE3)
- Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets (PHASE3)
- REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Full dose of DOAC CI brief — competitive landscape report
- Full dose of DOAC updates RSS · CI watch RSS
- University Hospital, Brest portfolio CI